News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fighting For The Next Asthma Blockbuster: Italy Gets In The Way Of Novartis AG (NVS)



11/22/2016 7:04:01 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024?

Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the British Atopix Therapeutics for an amount that could exceed €75M if all milestones are met. With this deal, Chiesi incorporates OC459, a CRTh2 antagonist, to its pipeline. The drug candidate is currently in Phase II to treat eosinophilic asthma, a severe condition that affects 40% of the population.

Read at News Release


comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES